openPR Logo
Press release

Rising Incidence And Mortality Rates To Drive Market Growth: Strategic Insights Driving Blood Cancer Drugs Market Momentum in 2025

08-19-2025 10:17 AM CET | Health & Medicine

Press release from: The Business Research Company

Blood Cancer Drugs Market Size

Blood Cancer Drugs Market Size

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Blood Cancer Drugs Market Size By 2025?
Recent years have seen significant growth in the size of the blood cancer drugs market. It's estimated to increase from $74.78 billion in 2024 to $80.79 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this historic growth include advancements in R&D, an aging demographic, heightened awareness and early diagnosis, and regulator approvals.

How Big Is the Blood Cancer Drugs Market Size Expected to Grow by 2029?
Expectations are high for the blood cancer drugs market to experience robust growth in the coming years. The market size is projected to increase to $106.8 billion in 2029, with an annual compound growth rate (CAGR) of 7.2%. The predicted growth during this period is largely attributed to the rising incidence of the disease, the emergence of new markets, and increased supportive care. Some of the significant trends anticipated during this forecast period include investment in research and development, adoption of combination therapies, identification of biomarkers, advancement in immunotherapy, and the development of personalized medicine.

View the full report here:
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Which Key Market Drivers Powering Blood Cancer Drugs Market Expansion and Growth?
The surge in the blood cancer drugs market is a direct consequence of increasing death rates and the rising prevalence of blood cancer across the world. Various forms of blood cancers such as leukemia, lymphoma, myeloma, and others have differing risk factors; while some are preventable or manageable through medication, others could lead to fatalities. For example, a report by Bristol-Myers Squibb Company in November 2022 indicated that over 1.85 million new cases of blood cancer are projected to be diagnosed worldwide in 2040. This figure includes 918,872 lymphoma cases, 656,345 leukemia cases, and 275,047 myeloma cases. Furthermore, the report predicts approximately 1,100,000 deaths worldwide from blood cancer in 2040. This increasing mortality rate and the escalating numbers of blood cancer diagnoses globally act as strong stimulants for the blood cancer drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Blood Cancer Drugs Market?
Key players in the blood cancer drugs market are concentrating their efforts on the creation of new drugs and obtaining FDA approval, in order to secure a competitive advantage. FDA approval is the official endorsement given by the U.S. Food and Drug Administration (FDA) that allows a pharmaceutical product to be marketed and sold legally within the United States. For example, Bristol Myers Squibb, a pharmaceutical firm based in the US, secured FDA approval for its first and exclusive CAR T-cell therapy for adults with recurrent or resistant chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in March 2024. This expedited approval permits its application in patients who have undergone at least two previous treatments, such as a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. In the TRANSCEND CLL 004 trial, Breyanzi showed a complete response rate of 20% and a median duration of response of 35.3 months among responders.

What Are the Emerging Segments in the Blood Cancer Drugs Market?
The blood cancer drugs market covered in this report is segmented -

1) By Blood Cancer Type: Leukemia, Lymphoma
2) By Drugs: Rituxan Or Mabthera (Rituximab), Gleevec Or Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs
3) By Treatment Approaches: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic

Subsegments:
1) By Leukemia: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Other Types of Leukemia
2) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Burkitt Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Other Types of Lymphoma

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2587&type=smp

Who Are the Global Leaders in the Blood Cancer Drugs Market?
Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated

Which are the Top Profitable Regional Markets for the Blood Cancer Drugs Industry?
North America was the largest region in the blood cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2587

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rising Incidence And Mortality Rates To Drive Market Growth: Strategic Insights Driving Blood Cancer Drugs Market Momentum in 2025 here

News-ID: 4149261 • Views:

More Releases from The Business Research Company

Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Forecast Report
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025? The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of
Sustained Release Excipients Market Advances With Product Innovation Industry Trends Gaining Momentum in the Global Sustained Release Excipients Market
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025? In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therapeutics Market Driving Market Acceleration in the RNA Targeting Small Molecules Therapeutics Industry, 2025
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025? In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as a Core Driver of the Remicade Biosimilar Market in 2025
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025? In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic

All 5 Releases


More Releases for Drug

Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights: * Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029 * Global and Regional Antibody Drug Conjugate Market Insight * Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023 * Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight * Insight On Antibody Drug Conjugates In Clinical Trials: > 550
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase